Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06472245
Title Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor (ARTEMIA)
Acronym ARTEMIA
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors OSE Immunotherapeutics
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Georgetown Lombardi Comprehensive Cancer Center Washington District of Columbia 20007 United States Details
Alliance for Multispecialty Research (AMR) - Kansas City Oncology Merriam Kansas 66204 United States Details
NHO Revive Research Institute LLC Lincoln Nebraska 68506 United States Details
Optum Medical Care - Carmel/Brewster Campus Brewster New York 10509-2338 United States Details
Optum Medical Care - Fishkill Westage Campus Fishkill New York 12524 United States Details
Optum Hematology Oncology - Lake Success Lake Success New York 11042 United States Details
Optum Medical Care - Mount Kisco Campus 90 Mount Kisco New York 10549 United States Details
Optum Medical Care - Poughkeepsie Poughkeepsie New York 12601 United States Details
Brooklyn Radiation Oncology Richmond Hill New York 11418 United States Details
Bon Secours Hematology and Oncology Greenville South Carolina 29607 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field